Bibekanand Mallick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Bibekanand Mallick has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Zhumur Ghosh
Department of Biological Sciences, Bose Institute, Unified Academic Campus, Kolkata-700 091, India
12 shared publications - Jyoti Roy
RNAi and Functional Genomics Lab, Department of Life Science, National Institute of Technology, Rourkela, Odisha, India
11 shared publications Jayprokas Chakrabarti
8 shared publicationsNeha Jain
RNAi and Functional Genomics Lab., Department of Life Science, National Institute of Technology, Rourkela 769008, Odisha, India
8 shared publicationsMousumi Sahu
RNAi and Functional Genomics Laboratory, Department of Life Science, National Institute of Technology, Rourkela, Odisha, India
7 shared publicationsTrisha Chattopadhyay
RNAi and Functional Genomics Lab., Department of Life Science, National Institute of Technology Rourkela, Rourkela, 769008, Odisha, India
7 shared publications
Latest Publications
- 25 June 2026
- Published by Elsevier in Computational Biology and Chemistry
- Vol. 124 (Pt 2) , 109211
Integrated omics and virtual screening predict Tabularin as a dual inhibitor of the prognostic microRNAs mir-19a and mir-32 in colorectal cancer
- 25 June 2026
- Published by Elsevier in Computational Biology and Chemistry
- Vol. 124 (Pt 2) , 109211
Integrated omics and virtual screening predict Tabularin as a dual inhibitor of the prognostic microRNAs mir-19a and mir-32 in colorectal cancer
- 3 February 2026
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 778, 110756
Cisplatin disrupts OCT1-DNMT1-piRNA epigenetic regulatory axis to suppress GAB2-mediated aggressiveness in OSCC
- 3 February 2026
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 778, 110756
Cisplatin disrupts OCT1-DNMT1-piRNA epigenetic regulatory axis to suppress GAB2-mediated aggressiveness in OSCC
- 15 November 2025
- Published by Wiley in IUBMB Life
- Vol. 77 (11) , e70077
Silent Guardians Gone Rogue: The Role of PIWI and piRNA in Malignant Transformation
Malignant transformation is not merely the consequence of stochastic genetic mutations but rather a convergence of complex interplay between genetic, epigenetic, and environmental factors that collectively reprogram normal cells into cancerous ones. Central to these processes is the loss of tumor suppressor genes, activation of oncogenes, chromosomal instability, and widespread epigenetic remodeling. A pivotal aspect of this transformation involves the contribution of ncRNAs that have been recurrently implicated in malignant transformation. While much attention is directed toward miRNAs, circRNAs, and lncRNAs, piRNAs have remained comparatively overlooked in cancer biology. This is despite a growing body of evidence implicating piRNAs in regulating tumorigenic pathways, genomic stability, and epigenetic gene silencing. Our review explores the emerging role of the piRNAs and their regulatory protein PIWI in modulating key malignant features, including hyperproliferation, EMT, tumor evasion, migration, angiogenesis, and others. We also examine how this axis influences the initiation and progression of cancer, highlighting its potential to reshape established paradigms in cancer studies.
- 15 November 2025
- Published by Wiley in IUBMB Life
- Vol. 77 (11) , e70077
Silent Guardians Gone Rogue: The Role of PIWI and piRNA in Malignant Transformation
Malignant transformation is not merely the consequence of stochastic genetic mutations but rather a convergence of complex interplay between genetic, epigenetic, and environmental factors that collectively reprogram normal cells into cancerous ones. Central to these processes is the loss of tumor suppressor genes, activation of oncogenes, chromosomal instability, and widespread epigenetic remodeling. A pivotal aspect of this transformation involves the contribution of ncRNAs that have been recurrently implicated in malignant transformation. While much attention is directed toward miRNAs, circRNAs, and lncRNAs, piRNAs have remained comparatively overlooked in cancer biology. This is despite a growing body of evidence implicating piRNAs in regulating tumorigenic pathways, genomic stability, and epigenetic gene silencing. Our review explores the emerging role of the piRNAs and their regulatory protein PIWI in modulating key malignant features, including hyperproliferation, EMT, tumor evasion, migration, angiogenesis, and others. We also examine how this axis influences the initiation and progression of cancer, highlighting its potential to reshape established paradigms in cancer studies.
- 30 October 2024
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51 (1) , 1-26
miR-128-3p suppresses tumor growth and enhances chemosensitivity in tongue squamous cell carcinoma through MAP2K7 targeting
Background MicroRNAs (miRNAs), which are key players in cancer cell resistance to chemotherapy, notably target genes associated with drug resistance. While miRNA-128-3p is recognized for its involvement in various cancers, its specific role in tumorigenesis and cisplatin (CIS) resistance in tongue cancer remains unclear. Therefore, in the present study, we endeavoured to elucidate the significance of miR-128-3p in tongue squamous cell carcinoma (TSCC), shedding light on its intricate functions and underlying mechanisms. Methods and results We quantified the expression of miR-128-3p and its target genes using qRT-PCR, followed by a series of functional assays in vitro, such as proliferation and migration assays, flow cytometry analysis, and western blotting to unravel the mechanisms underlying the functions of miR-128-3p. Additionally, we validated the ability of miR-128-3p to target MAP2K7 genes through luciferase reporter assays. We observed that increased expression of miR-128-3p significantly inhibited TSCC cell migration, proliferation, and epithelial-mesenchymal transition (EMT), possibly by regulating MAP2K7 in the JNK/MAP kinase pathway through miRNA target binding. Furthermore, we showed that increased miR-128-3p levels enhanced the sensitivity of TSCC cells to CIS through the JNK/c-Jun cascade. We observed that miR-128-3p reduces the expression of c-Jun and ABC transporter genes by targeting MAP2K7, affecting JNK1/2. This inhibition possibly decreases drug efflux and thus enhances the TSCC sensitivity to CIS treatment. Conclusions Our findings demonstrate oncosuppressive behaviour of miR-128-3p, which also potentially enhances the sensitivity of TSCC cells to CIS by suppressing MAP2K7 and JNK1/2, leading to evasion of apoptosis. Graphical Abstract
- 30 October 2024
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51 (1) , 1-26
miR-128-3p suppresses tumor growth and enhances chemosensitivity in tongue squamous cell carcinoma through MAP2K7 targeting
Background MicroRNAs (miRNAs), which are key players in cancer cell resistance to chemotherapy, notably target genes associated with drug resistance. While miRNA-128-3p is recognized for its involvement in various cancers, its specific role in tumorigenesis and cisplatin (CIS) resistance in tongue cancer remains unclear. Therefore, in the present study, we endeavoured to elucidate the significance of miR-128-3p in tongue squamous cell carcinoma (TSCC), shedding light on its intricate functions and underlying mechanisms. Methods and results We quantified the expression of miR-128-3p and its target genes using qRT-PCR, followed by a series of functional assays in vitro, such as proliferation and migration assays, flow cytometry analysis, and western blotting to unravel the mechanisms underlying the functions of miR-128-3p. Additionally, we validated the ability of miR-128-3p to target MAP2K7 genes through luciferase reporter assays. We observed that increased expression of miR-128-3p significantly inhibited TSCC cell migration, proliferation, and epithelial-mesenchymal transition (EMT), possibly by regulating MAP2K7 in the JNK/MAP kinase pathway through miRNA target binding. Furthermore, we showed that increased miR-128-3p levels enhanced the sensitivity of TSCC cells to CIS through the JNK/c-Jun cascade. We observed that miR-128-3p reduces the expression of c-Jun and ABC transporter genes by targeting MAP2K7, affecting JNK1/2. This inhibition possibly decreases drug efflux and thus enhances the TSCC sensitivity to CIS treatment. Conclusions Our findings demonstrate oncosuppressive behaviour of miR-128-3p, which also potentially enhances the sensitivity of TSCC cells to CIS by suppressing MAP2K7 and JNK1/2, leading to evasion of apoptosis. Graphical Abstract
- 10 September 2024
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 761, 110150
Unlocking the potential of signature-based drug repurposing for anticancer drug discovery
- 10 September 2024
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 761, 110150
Unlocking the potential of signature-based drug repurposing for anticancer drug discovery
- 26 August 2024
- Published by Elsevier in Cancer Genetics
- Vol. 288-289, 20-31
BMS345541 is predicted as a repurposed drug for the treatment of TMZ-resistant Glioblastoma using target gene expression and virtual drug screening
- 26 August 2024
- Published by Elsevier in Cancer Genetics
- Vol. 288-289, 20-31
BMS345541 is predicted as a repurposed drug for the treatment of TMZ-resistant Glioblastoma using target gene expression and virtual drug screening